Last checked at 
Angle PLC - Surrey, England-based medical diagnostics company - Notes researchers at King's College London published data investigating the role of invasive cellular protrusion, known as invadopodia, activity in prostate cancer, and a potential role in the formation of circulating tumour cells. Researchers used Angle's Parsortix system's ability to isolate CTCs from the blood of prostate cancer patients. Parsortix system isolates CTCs in 94% of prostate cancer patients, showing some association with matrix degradation and invasive cellular protrusion formation. This may allow novel therapeutic development targeting the mechanisms of invadopodia and reducing metastatic spread of the cancer, it says.
Chief Executive Officer Andrew Newland, added: "We are pleased to report on the use of the Parsortix system for the unbiased isolation of CTCs in prostate cancer, revealing a potentially novel understanding of prostate cancer CTC formation. This research suggests a potential for the development of novel therapeutics targeting the early stages of prostate cancer metastasis, which is important for improving patient survival."
Current stock price: 105.00p
12-month change: down 19%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
